The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells
Abstract
The interleukin (IL) 13 receptor α2 (IL13Rα2) is a glioma-restricted cell-surface epitope not otherwise detected within the central nervous system. Here, we describe a novel approach for targeting glioblastoma multiforme (GBM) with IL13Rα2-specific cytolytic T cells (CTLs) by their genetic modification to express a membrane-tethered IL13 cytokine chimeric T-cell antigen receptor, or zetakine. Our prototype zetakine incorporates an IL13 E13Y mutein for selective binding to IL13Rα2. Human IL13-zetakine+CD8+ CTL transfectants display IL13Rα2-specific antitumor effector function including tumor cell cytolysis, TC1 cytokine production, and zetakine-regulated autocrine proliferation. The E13Y amino acid substitution of the IL13 mutein of the zetakine endows CTL transfectants with the capacity to discriminate between IL13Rα2+ GBM targets from targets expressing IL13Rα1. In vivo, the adoptive transfer of IL13-zetakine+CD8+ CTL clones results in the regression of established human glioblastoma orthotopic xenografts. Pilot clinical trials have been initiated to evaluate the feasibility and safety of local-regional delivery of autologous IL13-zetakine redirected CTL clones in patients with recurrent GBM. Our IL13-zetakine is a prototype of a new class of chimeric immunoreceptors that signal through an engineered immune synapse composed of membrane-tethered cytokine muteins bound to cell-surface cytokine receptors on tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Roles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism
Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T., & Curiel, D. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6839-6846.1996 · Cited by 387
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
Self-citationLampson, L. A., & Hickey, W. F. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.11.4054 · Cited by 227
Debinski, W., Obiri, N. I., Powers, S. K., Pastan, I. H., & Puri, R. K. (1995) · PubMed · Cited by 216
Lupton, S. D., Brunton, L. L., Kalberg, V. A., & Overell, R. W. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.6.3374-3378.1991 · Cited by 164
Debinski, W., & Gibo, D. M. (2000) · Molecular Medicine · doi:10.1007/bf03401786 · Cited by 142
Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside
Husain, S. R., & Puri, R. K. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026242432647 · Cited by 119
Cited by
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Self-citationLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Self-citationTandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Metadata
- Authors
- Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C.
- Venue
- Cancer Research
- Published
- 2004-12-15
- Volume
- 64
- Issue
- 24
- Pages
- 9160-9166
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2039721940
- Cited by
- 368
- References
- 16
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-0454
- The paper
- Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004). Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-0454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.